The increase experienced in the domestic industry with the incentives issued by the government in a program with the pharmaceutical industry among primary strategic products, drew the attention of top pharma players to Turkey.
Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorisation of ABP 980, a biosimilar to Herceptin®.
Amgen and Pharmstandard announced the signing of an agreement on technology transfer, manufacturing and commercialization of blinatumomab in the Russian market
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK
